טוען...
ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma
MEK-ERK1/2 signaling is elevated in melanomas that are wild-type for both BRAF and NRAS (WT/WT), but patients are insensitive to MEK inhibitors. Stromal-derived growth factors may mediate resistance to targeted inhibitors, and optimizing the use of targeted inhibitors for WT/WT melanoma patients is...
שמור ב:
| הוצא לאור ב: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6168374/ https://ncbi.nlm.nih.gov/pubmed/30115691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-1001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|